Thorner M O, McNeilly A S, Hagan C, Besser G M
Br Med J. 1974 May 25;2(5916):419-22. doi: 10.1136/bmj.2.5916.419.
Seventeen women and four men with galactorrhoea and associated hypogonadism have been treated with bromocriptine for 2 to 28 months. In 18 patients the gonadal status became normal as the galactorrhoea improved. The gonadally unresponsive patients had either pituitary tumours or premature menopause. Prolactin levels fell with treatment; withdrawal of the drug was associated with an increase in serum prolactin and a recurrence of the galactorrhoea and hypogonadism. Two patients tried to become pregnant on treatment and both succeeded. Raised prolactin levels appear to block the actions of the gonadotrophins at a gonadal level rather than prevent their synthesis or release; lowering prolactin secretion with bromocriptine allows resumption of normal gonadal function. Bromocriptine appears to be the treatment of choice for inappropriate lactation in association with hypogonadism on a long-term basis.
17名患有溢乳症及相关性腺功能减退的女性和4名男性接受了溴隐亭治疗,疗程为2至28个月。18例患者的性腺状况随着溢乳症的改善而恢复正常。性腺无反应的患者患有垂体肿瘤或过早绝经。治疗后催乳素水平下降;停药后血清催乳素升高,溢乳症和性腺功能减退复发。两名患者在治疗期间尝试怀孕,均成功。升高的催乳素水平似乎在性腺水平阻断了促性腺激素的作用,而不是阻止其合成或释放;用溴隐亭降低催乳素分泌可使性腺功能恢复正常。长期来看,溴隐亭似乎是治疗伴有性腺功能减退的不适当泌乳的首选药物。